Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

NSAIDs and Colorectal Cancer Control: Promise and Challenges.

Tsioulias GJ, Go MF, Rigas B.

Curr Pharmacol Rep. 2015 Oct 1;1(5):295-301. Epub 2015 May 14.

PMID:
26688785
2.

PPARĪ“ and PGE2 signaling pathways communicate and connect inflammation to colorectal cancer.

Wang D, DuBois RN.

Inflamm Cell Signal. 2014 Oct 19;1(6). doi: 10.14800/ics.338.

3.

Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.

Ait Ouakrim D, Dashti SG, Chau R, Buchanan DD, Clendenning M, Rosty C, Winship IM, Young JP, Giles GG, Leggett B, Macrae FA, Ahnen DJ, Casey G, Gallinger S, Haile RW, Le Marchand L, Thibodeau SN, Lindor NM, Newcomb PA, Potter JD, Baron JA, Hopper JL, Jenkins MA, Win AK.

J Natl Cancer Inst. 2015 Jun 24;107(9). pii: djv170. doi: 10.1093/jnci/djv170. Print 2015 Sep.

PMID:
26109217
4.

A multi-targeted approach to suppress tumor-promoting inflammation.

Samadi AK, Bilsland A, Georgakilas AG, Amedei A, Amin A, Bishayee A, Azmi AS, Lokeshwar BL, Grue B, Panis C, Boosani CS, Poudyal D, Stafforini DM, Bhakta D, Niccolai E, Guha G, Vasantha Rupasinghe HP, Fujii H, Honoki K, Mehta K, Aquilano K, Lowe L, Hofseth LJ, Ricciardiello L, Ciriolo MR, Singh N, Whelan RL, Chaturvedi R, Ashraf SS, Shantha Kumara HM, Nowsheen S, Mohammed SI, Keith WN, Helferich WG, Yang X.

Semin Cancer Biol. 2015 Dec;35 Suppl:S151-84. doi: 10.1016/j.semcancer.2015.03.006. Epub 2015 May 5. Review.

5.

The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimism.

Rigas B, Tsioulias GJ.

J Pharmacol Exp Ther. 2015 Apr;353(1):2-8. Review.

PMID:
25589413
6.

Non-steroidal anti-inflammatory drugs use is associated with reduced risk of inflammation-associated cancers: NIH-AARP study.

Shebl FM, Hsing AW, Park Y, Hollenbeck AR, Chu LW, Meyer TE, Koshiol J.

PLoS One. 2014 Dec 31;9(12):e114633. doi: 10.1371/journal.pone.0114633. eCollection 2014.

7.

A systematic review of aspirin in primary prevention: is it time for a new approach?

Brotons C, Benamouzig R, Filipiak KJ, Limmroth V, Borghi C.

Am J Cardiovasc Drugs. 2015 Apr;15(2):113-33. doi: 10.1007/s40256-014-0100-5. Review.

8.

Chemoprevention in patients with genetic risk of colorectal cancers.

Laukaitis CM, Erdman SH, Gerner EW.

Colorectal Cancer. 2012;1(3):225-240.

9.

Role of inflammation and inflammatory mediators in colorectal cancer.

Dubois RN.

Trans Am Clin Climatol Assoc. 2014;125:358-72; discussion 372-3.

10.

Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis.

Li B, Flaveny CA, Giambelli C, Fei DL, Han L, Hang BI, Bai F, Pei XH, Nose V, Burlingame O, Capobianco AJ, Orton D, Lee E, Robbins DJ.

PLoS One. 2014 Jul 8;9(7):e101969. doi: 10.1371/journal.pone.0101969. eCollection 2014.

11.

Aspirin, cyclooxygenase inhibition and colorectal cancer.

Sostres C, Gargallo CJ, Lanas A.

World J Gastrointest Pharmacol Ther. 2014 Feb 6;5(1):40-9. doi: 10.4292/wjgpt.v5.i1.40. Review.

12.

Attenuated familial adenomatous polyposis manifests as autosomal dominant late-onset colorectal cancer.

Ibrahim A, Barnes DR, Dunlop J, Barrowdale D, Antoniou AC, Berg JN.

Eur J Hum Genet. 2014 Nov;22(11):1330-3. doi: 10.1038/ejhg.2014.20. Epub 2014 Feb 19.

13.

Mechanistic and pharmacological issues of aspirin as an anticancer agent.

Dovizio M, Tacconelli S, Sostres C, Ricciotti E, Patrignani P.

Pharmaceuticals (Basel). 2012 Dec 5;5(12):1346-71. doi: 10.3390/ph5121346.

14.

Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial.

Ishikawa H, Wakabayashi K, Suzuki S, Mutoh M, Hirata K, Nakamura T, Takeyama I, Kawano A, Gondo N, Abe T, Tokudome S, Goto C, Matsuura N, Sakai T.

Cancer Med. 2013 Feb;2(1):50-6. doi: 10.1002/cam4.46. Epub 2013 Feb 3.

15.

Potential targets for colorectal cancer prevention.

Temraz S, Mukherji D, Shamseddine A.

Int J Mol Sci. 2013 Aug 22;14(9):17279-303. doi: 10.3390/ijms140917279. Review.

16.

Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention.

Colussi D, Brandi G, Bazzoli F, Ricciardiello L.

Int J Mol Sci. 2013 Aug 7;14(8):16365-85. doi: 10.3390/ijms140816365. Review.

17.

The impact of aspirin, statins and ACE-inhibitors on the presentation of colorectal neoplasia in a colorectal cancer screening programme.

Mansouri D, McMillan DC, Roxburgh CS, Crighton EM, Horgan PG.

Br J Cancer. 2013 Jul 9;109(1):249-56. doi: 10.1038/bjc.2013.292. Epub 2013 Jun 18.

18.

Identification of putative immunologic targets for colon cancer prevention based on conserved gene upregulation from preinvasive to malignant lesions.

Broussard EK, Kim R, Wiley JC, Marquez JP, Annis JE, Pritchard D, Disis ML.

Cancer Prev Res (Phila). 2013 Jul;6(7):666-74. doi: 10.1158/1940-6207.CAPR-12-0484. Epub 2013 May 16.

19.

Thymoquinone attenuates tumor growth in ApcMin mice by interference with Wnt-signaling.

Lang M, Borgmann M, Oberhuber G, Evstatiev R, Jimenez K, Dammann KW, Jambrich M, Khare V, Campregher C, Ristl R, Gasche C.

Mol Cancer. 2013 May 13;12(1):41. doi: 10.1186/1476-4598-12-41.

20.

Chemoprevention of gastrointestinal cancer: the reality and the dream.

Chun KS, Kim EH, Lee S, Hahm KB.

Gut Liver. 2013 Mar;7(2):137-49. doi: 10.5009/gnl.2013.7.2.137. Epub 2013 Feb 7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk